Focus: Edesa Biotech is a public Canadian biotech company focused on topical and suppository formulations, primarily in neurology and immunology indications. The company operates at an early clinical stage with a lean R&D footprint.
Profile data last refreshed 56m ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Edesa Biotech to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Edesa Biotech
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Edesa Biotech's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Edesa Biotech Schedules Phase 2 Vitiligo Study for Mid-2026 - HarianBasis.co
Edesa Biotech Schedules Phase 2 Vitiligo Study for Mid-2026 HarianBasis.co
Acute Respiratory Distress Syndrome Clinical Trial Pipeline Shows Potential with Active Contributions from 40+ Key Companies | DelveInsight - Dailyhunt
Acute Respiratory Distress Syndrome Clinical Trial Pipeline Shows Potential with Active Contributions from 40+ Key Companies | DelveInsight Dailyhunt
Vitiligo drug study moves ahead as Edesa picks trial manager - Stock Titan
Vitiligo drug study moves ahead as Edesa picks trial manager Stock Titan
Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment - Yahoo Finance
Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment Yahoo Finance
If You Invested $1,000 in Edesa Biotech Inc (EDSA) - Stock Titan
If You Invested $1,000 in Edesa Biotech Inc (EDSA) Stock Titan
Edesa Biotech Advances on Promising Drug Trial Results - timothysykes.com
Edesa Biotech Advances on Promising Drug Trial Results timothysykes.com
Showing 6 of 9 news items
No open positions listed yet. Check their careers page directly.
Lack of transparency on workforce size and recent inactivity are red flags; company may be in survival mode.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo